In vitro antibacterial activity of tigecycline against clinical isolates of Linezolid-Intermediate (LIE) and Linezolid-Resistant Enterococci (LRE) by time-kill assay

Detalhes bibliográficos
Autor(a) principal: Sambrano, Gustavo Enck
Data de Publicação: 2014
Outros Autores: Paim, Thiago Galvão da Silva, da Silva, Lucas Toniolo, d'Azevedo, Pedro Alves
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Clinical and Biomedical Research
Texto Completo: https://seer.ufrgs.br/index.php/hcpa/article/view/48369
Resumo: Introduction: Enterococci have become the third major leading cause of nosocomial bacteraemia, an infection which is significantly associated with the risk of developing infective endocarditis. Linezolid provides high rates of clinical cure and microbiologic success in complicated infections due to Enterococcus spp. However, several instances of emergence of resistance during linezolid treatment have been reported. The aim of this study was evaluate the activity of tigecycline against Linezolid-Intermediate (LIE) and Linezolid-Resistant Enterococcus faecalis (LRE) by the time-kill assay.Methods: Five isolates of LRE and two isolates of LIE were used in this study. MICs were determined by broth dilution following the CLSI (2014) guidelines. Time-kill assay was employed to access the in vitro response profile of tigecycline.Results: All seven of the isolates presented MIC of 0.125μg/mL. Tigecycline activity was individually evaluated and in three of the five isolates of LRE it presented bactericidal. Against the other isolates, tigecycline showed bacteriostatic activity. The tigecycline activity was measured according to CLSI criteria.Conclusions: Tigecycline presented both bacteriostatic and bactericidal activity against tested isolates, result not yet described in previous studies. Time and concentrations above MIC were key factors to achieving bactericidal effect. MIC and the tested concentration below it resulted in bacteriostatical effect to enterococci, corroborating previous data.
id UFRGS-20_992c76848a5442520d7c9b2e49110811
oai_identifier_str oai:seer.ufrgs.br:article/48369
network_acronym_str UFRGS-20
network_name_str Clinical and Biomedical Research
repository_id_str
spelling In vitro antibacterial activity of tigecycline against clinical isolates of Linezolid-Intermediate (LIE) and Linezolid-Resistant Enterococci (LRE) by time-kill assayEnterococcusAnti-Infective AgentsBacterial GrowthMicrobiologiaIntroduction: Enterococci have become the third major leading cause of nosocomial bacteraemia, an infection which is significantly associated with the risk of developing infective endocarditis. Linezolid provides high rates of clinical cure and microbiologic success in complicated infections due to Enterococcus spp. However, several instances of emergence of resistance during linezolid treatment have been reported. The aim of this study was evaluate the activity of tigecycline against Linezolid-Intermediate (LIE) and Linezolid-Resistant Enterococcus faecalis (LRE) by the time-kill assay.Methods: Five isolates of LRE and two isolates of LIE were used in this study. MICs were determined by broth dilution following the CLSI (2014) guidelines. Time-kill assay was employed to access the in vitro response profile of tigecycline.Results: All seven of the isolates presented MIC of 0.125μg/mL. Tigecycline activity was individually evaluated and in three of the five isolates of LRE it presented bactericidal. Against the other isolates, tigecycline showed bacteriostatic activity. The tigecycline activity was measured according to CLSI criteria.Conclusions: Tigecycline presented both bacteriostatic and bactericidal activity against tested isolates, result not yet described in previous studies. Time and concentrations above MIC were key factors to achieving bactericidal effect. MIC and the tested concentration below it resulted in bacteriostatical effect to enterococci, corroborating previous data.HCPA/FAMED/UFRGS2014-08-25info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionPeer-reviewed ArticleAvaliado por Paresapplication/pdfhttps://seer.ufrgs.br/index.php/hcpa/article/view/48369Clinical & Biomedical Research; Vol. 34 No. 3 (2014): Clinical and Biomedical ResearchClinical and Biomedical Research; v. 34 n. 3 (2014): Clinical and Biomedical Research2357-9730reponame:Clinical and Biomedical Researchinstname:Universidade Federal do Rio Grande do Sul (UFRGS)instacron:UFRGSenghttps://seer.ufrgs.br/index.php/hcpa/article/view/48369/31848Sambrano, Gustavo EnckPaim, Thiago Galvão da Silvada Silva, Lucas Toniolod'Azevedo, Pedro Alvesinfo:eu-repo/semantics/openAccess2024-01-19T13:30:54Zoai:seer.ufrgs.br:article/48369Revistahttps://www.seer.ufrgs.br/index.php/hcpaPUBhttps://seer.ufrgs.br/index.php/hcpa/oai||cbr@hcpa.edu.br2357-97302357-9730opendoar:2024-01-19T13:30:54Clinical and Biomedical Research - Universidade Federal do Rio Grande do Sul (UFRGS)false
dc.title.none.fl_str_mv In vitro antibacterial activity of tigecycline against clinical isolates of Linezolid-Intermediate (LIE) and Linezolid-Resistant Enterococci (LRE) by time-kill assay
title In vitro antibacterial activity of tigecycline against clinical isolates of Linezolid-Intermediate (LIE) and Linezolid-Resistant Enterococci (LRE) by time-kill assay
spellingShingle In vitro antibacterial activity of tigecycline against clinical isolates of Linezolid-Intermediate (LIE) and Linezolid-Resistant Enterococci (LRE) by time-kill assay
Sambrano, Gustavo Enck
Enterococcus
Anti-Infective Agents
Bacterial Growth
Microbiologia
title_short In vitro antibacterial activity of tigecycline against clinical isolates of Linezolid-Intermediate (LIE) and Linezolid-Resistant Enterococci (LRE) by time-kill assay
title_full In vitro antibacterial activity of tigecycline against clinical isolates of Linezolid-Intermediate (LIE) and Linezolid-Resistant Enterococci (LRE) by time-kill assay
title_fullStr In vitro antibacterial activity of tigecycline against clinical isolates of Linezolid-Intermediate (LIE) and Linezolid-Resistant Enterococci (LRE) by time-kill assay
title_full_unstemmed In vitro antibacterial activity of tigecycline against clinical isolates of Linezolid-Intermediate (LIE) and Linezolid-Resistant Enterococci (LRE) by time-kill assay
title_sort In vitro antibacterial activity of tigecycline against clinical isolates of Linezolid-Intermediate (LIE) and Linezolid-Resistant Enterococci (LRE) by time-kill assay
author Sambrano, Gustavo Enck
author_facet Sambrano, Gustavo Enck
Paim, Thiago Galvão da Silva
da Silva, Lucas Toniolo
d'Azevedo, Pedro Alves
author_role author
author2 Paim, Thiago Galvão da Silva
da Silva, Lucas Toniolo
d'Azevedo, Pedro Alves
author2_role author
author
author
dc.contributor.author.fl_str_mv Sambrano, Gustavo Enck
Paim, Thiago Galvão da Silva
da Silva, Lucas Toniolo
d'Azevedo, Pedro Alves
dc.subject.por.fl_str_mv Enterococcus
Anti-Infective Agents
Bacterial Growth
Microbiologia
topic Enterococcus
Anti-Infective Agents
Bacterial Growth
Microbiologia
description Introduction: Enterococci have become the third major leading cause of nosocomial bacteraemia, an infection which is significantly associated with the risk of developing infective endocarditis. Linezolid provides high rates of clinical cure and microbiologic success in complicated infections due to Enterococcus spp. However, several instances of emergence of resistance during linezolid treatment have been reported. The aim of this study was evaluate the activity of tigecycline against Linezolid-Intermediate (LIE) and Linezolid-Resistant Enterococcus faecalis (LRE) by the time-kill assay.Methods: Five isolates of LRE and two isolates of LIE were used in this study. MICs were determined by broth dilution following the CLSI (2014) guidelines. Time-kill assay was employed to access the in vitro response profile of tigecycline.Results: All seven of the isolates presented MIC of 0.125μg/mL. Tigecycline activity was individually evaluated and in three of the five isolates of LRE it presented bactericidal. Against the other isolates, tigecycline showed bacteriostatic activity. The tigecycline activity was measured according to CLSI criteria.Conclusions: Tigecycline presented both bacteriostatic and bactericidal activity against tested isolates, result not yet described in previous studies. Time and concentrations above MIC were key factors to achieving bactericidal effect. MIC and the tested concentration below it resulted in bacteriostatical effect to enterococci, corroborating previous data.
publishDate 2014
dc.date.none.fl_str_mv 2014-08-25
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
Peer-reviewed Article
Avaliado por Pares
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://seer.ufrgs.br/index.php/hcpa/article/view/48369
url https://seer.ufrgs.br/index.php/hcpa/article/view/48369
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv https://seer.ufrgs.br/index.php/hcpa/article/view/48369/31848
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv HCPA/FAMED/UFRGS
publisher.none.fl_str_mv HCPA/FAMED/UFRGS
dc.source.none.fl_str_mv Clinical & Biomedical Research; Vol. 34 No. 3 (2014): Clinical and Biomedical Research
Clinical and Biomedical Research; v. 34 n. 3 (2014): Clinical and Biomedical Research
2357-9730
reponame:Clinical and Biomedical Research
instname:Universidade Federal do Rio Grande do Sul (UFRGS)
instacron:UFRGS
instname_str Universidade Federal do Rio Grande do Sul (UFRGS)
instacron_str UFRGS
institution UFRGS
reponame_str Clinical and Biomedical Research
collection Clinical and Biomedical Research
repository.name.fl_str_mv Clinical and Biomedical Research - Universidade Federal do Rio Grande do Sul (UFRGS)
repository.mail.fl_str_mv ||cbr@hcpa.edu.br
_version_ 1799767053650886656